ABSTRACT
The limitations of heparin and warfarin have prompted the search for new anticoagulants
for the prevention and treatment of venous and arterial thromboembolism. Although
many such agents are in development, only a few have reached phase II or higher levels
of clinical testing. This article reviews venous and arterial thrombogenesis, discusses
the regulation of coagulation, identifies the molecular targets for new anticoagulants
currently under development, describes the agents in more advanced stages of clinical
testing, and provides clinical perspective on the opportunities for new anticoagulant
drugs.
KEYWORDS
Anticoagulants - thromboembolism - heparin - warfarin - thrombin inhibitor - factor
Xa inhibitors